Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 300 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Peng Lu sold 300 shares of the company’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $34.00, for a total value of $10,200.00. Following the completion of the sale, the insider owned 65,631 shares in the company, valued at $2,231,454. This trade represents a 0.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Peng Lu also recently made the following trade(s):

• On Wednesday, April 29th, Peng Lu sold 3,733 shares of Pharvaris stock. The shares were sold at an average price of $30.06, for a total value of $112,213.98.
• On Thursday, April 30th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $30.24, for a total value of $453,600.00.
• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,380.05.

Pharvaris Trading Up 0.6%

NASDAQ:PHVS traded up $0.19 on Tuesday, reaching $33.19. 326,665 shares of the stock traded hands, compared to its average volume of 243,931. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of -10.44 and a beta of -2.35. The company’s 50 day moving average is $30.13 and its 200-day moving average is $27.82. Pharvaris N.V. has a 1-year low of $16.72 and a 1-year high of $34.41.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. On average, equities research analysts forecast that Pharvaris N.V. will post -3.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in shares of Pharvaris by 41.1% during the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after purchasing an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period. Legal & General Group Plc increased its position in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares in the last quarter. Amundi increased its position in Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after buying an additional 27,416 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Pharvaris by 19.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after buying an additional 7,879 shares during the period.

Wall Street Analyst Weigh In

PHVS has been the topic of a number of research analyst reports. Wolfe Research assumed coverage on shares of Pharvaris in a research report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target on the stock. HC Wainwright reissued a “buy” rating on shares of Pharvaris in a research report on Tuesday, June 16th. Wedbush boosted their price objective on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. UBS Group set a $74.00 target price on Pharvaris in a research report on Wednesday, May 13th. Finally, Citizens Jmp decreased their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.